OraSure Technologies updates highlight diagnostics focus amid shifting health trends
OraSure Technologies is focusing on its diagnostics and sampling portfolio, adapting to evolving demand for infectious-disease and at-home testing. The company, known for its rapid tests like OraQuick, aims to retain customers and launch new products as pandemic-driven demand normalizes, navigating a competitive market sensitive to funding and healthcare trends. Its stock performance is influenced by company news, sector rotation, and broader market sentiment for healthcare tools and diagnostics.
Form 4 OraSure Technologies Inc For: 30 June By Investing.com
This article reports on the filing of Form 4 by OraSure Technologies Inc for the period ending June 30. Form 4 is a document that must be filed with the SEC whenever there is a material change in the holdings of company insiders. The article indicates that OraSure Technologies Inc (OSUR) stock showed a 0.69% positive change.
OSUR - Orasure Technologies Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for Orasure Technologies Inc (OSUR) as of June 30. It includes information on market capitalization, sales, income, various ratios, insider and institutional ownership, and stock performance over different periods. The data indicates a recent closing price of $4.46 with a slight decrease.
OraSure Technologies (OSUR) director takes 3,666-share stock grant in lieu of cash
OraSure Technologies director Steven Kyle Boyd received a grant of 3,666 restricted shares of common stock, valued at $4.4325 per share, in lieu of cash director fees. This transaction, processed under the company's Stock Award Plan, immediately vested and increased Boyd's direct ownership to 163,234 common shares. The decision to accept stock instead of cash aligns with the company's Director Compensation Policy.
Form 4 OraSure Technologies Inc For: 30 June By Investing.com
This article from Investing.com announces the filing of Form 4 for OraSure Technologies Inc. for the period ending June 30. The brief piece includes a link to market data for OSUR and lists various stock market indices and commodity prices, as well as popular articles and market movers.
Form 4 OraSure Technologies Inc For: 30 June By Investing.com
This article from Investing.com reports on a Form 4 filing by OraSure Technologies Inc (OSUR) for the period ending June 30. The brief note indicates the filing's date and time and includes a link to relevant market data for the company.
Enterprise value to EBIT forward of OraSure Technologies, Inc. – MUN:EP3
The article focuses on the enterprise value to EBIT forward of OraSure Technologies, Inc. (MUN:EP3). It provides a high-level overview of the company's financial data on TradingView, listing it under Health Technology and Medical Specialties on the Munich Stock Exchange. The page likely offers detailed financial metrics for EP3 to investors.
Price to earnings forward of OraSure Technologies, Inc. – NASDAQ:OSUR
This article provides a financial overview of OraSure Technologies, Inc. (NASDAQ: OSUR), focusing on its forward price-to-earnings ratio. It seems to be a placeholder or a stub page from a financial data provider, as it primarily lists navigation and platform features rather than in-depth financial analysis. The content indicates that the market was closed at the time of access and no trades were recorded.
Price to book forward of OraSure Technologies, Inc. – NASDAQ:OSUR
The article presents the "Price to book forward" financial metric for OraSure Technologies, Inc. (NASDAQ: OSUR). It is a brief data point provided by TradingView, indicating a specific financial value for the company within a given period.
Price to book forward of OraSure Technologies, Inc. – LSX:881351
This page from TradingView provides financial information for OraSure Technologies, Inc. (LSX:881351), specifically focusing on its price-to-book forward ratio. The content indicates that the market is currently closed and shows no recent trades for the company.
Price to sales forward of OraSure Technologies, Inc. – LSX:881351
The article focuses on the "Price to sales forward" metric for OraSure Technologies, Inc. (LSX:881351) as of June 27, 2026. It appears to be a financial data snippet from a larger platform, indicating the company's valuation based on its forward sales. No specific financial figures are provided, but the context suggests it's a financial overview from TradingView, referencing data from ICE Data Services and FactSet.
Price to sales forward of OraSure Technologies, Inc. – NASDAQ:OSUR
The article displays the "Price to sales forward" metric for OraSure Technologies, Inc. (NASDAQ: OSUR) within the TradingView platform. It shows the period, value, change, and percentage change for this financial metric, indicating that the market was closed with no trades at the time of the data capture. The content is primarily a data snippet embedded within a finance platform's interface.
Price to earnings forward of OraSure Technologies, Inc. – LSX:881351
The article focuses on the "Price to earnings forward" metric for OraSure Technologies, Inc. (LSX:881351) as listed on the Lang & Schwarz Exchange. It appears to be a financial data page from TradingView, indicating that the market was closed at the time of viewing. The content primarily lists navigation and footer information rather than detailed financial analysis.
OraSure Technologies Inc (OSUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of OraSure Technologies Inc (OSUR), detailing its price momentum, support and resistance levels, and various technical indicators. As of June 17, 2026, the stock has a price momentum score of 9.48, and its technical indicators and moving averages largely signal a "Buy."
OraSure Technologies Inc (OSUR) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for OraSure Technologies Inc (OSUR), detailing its current earnings forecast score, analyst ratings, and price targets. The company ranks 66 out of 203 in the Healthcare Equipment & Supplies industry with an average price target of $4.50. Analysts largely recommend a "Buy" for OSUR stock, with an expected revenue of $28.83M for the next quarter.
OraSure Technologies Inc (OSUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for OraSure Technologies Inc (OSUR), categorizing its revenue by business segments and geographic regions. The company's main revenue streams come from Net product and services in HIV, Microbiome, and HCV, with the United States and Africa being its primary regional markets. The financial data is presented for various fiscal years and quarters, with the latest update on April 6th.
OraSure Technologies Inc (OSUR) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical dividend and stock split information for OraSure Technologies Inc (OSUR). It indicates that the company has distributed a total of 0.00 USD in dividends over the past five years and contains no data for historical stock splits. The article also provides current stock quotes and market capitalization for OSUR.
OSUR: At-Home STI Testing Expansion Will Drive Bullish Long-Term Outlook
OraSure Technologies' (OSUR) analyst price target remains at $4.75, with its fair value unchanged despite slight adjustments to discount rate, profit margin, and future P/E assumptions. Key news includes FDA clearance for its Colli-Pee™•Dx Urine Collection Kit to expand at-home STI testing, a board declassification amendment, and significant share repurchases. The company also entered a Cooperation Agreement with Altai Capital Management, adding an independent director to the board.
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies, Inc. announced FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, allowing at-home self-collection of urine samples for STI testing. This kit integrates with Roche's cobas® molecular diagnostic systems to detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. The clearance aims to expand access to STI testing by providing a convenient, private, and scalable solution, particularly benefiting individuals with mobility or geographical constraints.
OraSure gets FDA nod for at-home STI urine collection kit By Investing.com
OraSure Technologies Inc. received FDA clearance for its Colli-Pee Dx Urine Collection Kit, enabling at-home STI sample collection for use with Roche's diagnostic tests. This development aims to increase accessibility and convenience for patients, contributing to OraSure's stock performing well year-to-date, despite the company remaining unprofitable with recent missed earnings expectations. The kit uses NucleoPresicion Technology to maintain sample integrity, allowing for easy mail-in collection.
OraSure gets FDA nod for at-home STI urine collection kit
OraSure Technologies Inc. has received FDA clearance for its Colli-Pee Dx Urine Collection Kit, allowing at-home sample collection for Roche's sexually transmitted infection tests. This development makes STI testing more accessible and convenient for patients. Despite the positive news and a significant year-to-date stock return, OraSure remains unprofitable, with negative earnings and missed revenue expectations in its most recent quarterly report.
OraSure gets FDA nod for at-home STI urine collection kit
OraSure Technologies Inc. has received FDA clearance for its Colli-Pee Dx Urine Collection Kit, allowing at-home sample collection for sexually transmitted infection (STI) tests by Roche. This development aims to make STI testing more accessible and convenient. Despite recent positive stock performance, the company remains unprofitable, though it holds more cash than debt.
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies, Inc. announced FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, used with Roche’s molecular diagnostic systems for STIs. This clearance facilitates convenient at-home self-collection of urine samples, improving access to testing for conditions like Chlamydia, Gonorrhea, Trichomonas, and Mycoplasma genitalium. The technology enhances privacy, convenience, and scalability for STI screening programs.
OraSure receives FDA clearance for home urine collection kit for STIs
OraSure Technologies Inc., based in Bethlehem, has announced that its subsidiary DNA Genotek Inc. received FDA clearance for its Colli-Pee•Dx Urine Collection Kit. This kit enables convenient at-home self-collection of first-void urine for STI testing, supporting various Roche diagnostic systems. The clearance is a significant step towards patient-centric diagnostics, aiming to improve access, convenience, and privacy for STI screenings, particularly for underserved populations.
OraSure Technologies (NASDAQ: OSUR) wins FDA clearance for Colli-Pee Dx at-home urine collection kit
OraSure Technologies (NASDAQ: OSUR) has received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, developed by subsidiary DNA Genotek Inc. This kit is designed for at-home self-collection of first-void urine and is compatible with Roche Molecular Systems tests for several common sexually transmitted infections (STIs) on their cobas® 5800, 6800, and 8800 diagnostic systems. This clearance aims to expand convenient access to STI testing for both male and female patients by enabling remote sample collection.
OraSure secures FDA clearance for product seen as key to future growth
OraSure Technologies (NASDAQ: OSUR) has received FDA clearance for its Colli-Pee kit, an at-home urine collection device used for detecting sexually transmitted infections in conjunction with Roche's molecular diagnostic systems. This clearance is seen as crucial for the Bethlehem-based company's post-COVID growth, alongside another rapid molecular self-test for Chlamydia and gonorrhea developed by its subsidiary Sherlock Bioscienses, which is still awaiting FDA approval. Despite recent stock struggles, shares saw a more than 2% increase after the announcement.
FDA clears at-home urine kit that lets labs test for 4 STIs by mail
OraSure Technologies announced FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, which allows at-home, first-void urine self-collection for testing of four common sexually transmitted infections (STIs) in conjunction with Roche's cobas® molecular diagnostic systems. This clearance aims to expand patient access to STI testing by enabling scalable, mail-in, and decentralized testing, particularly for those facing mobility or geographical barriers. The kit includes proprietary stabilization technology to maintain sample integrity at ambient temperatures, making high-volume STI screening more feasible for laboratories and public health initiatives.
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies, Inc. has received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit. This kit, designed for at-home sample collection, will be used with Roche’s molecular lab testing equipment to detect common sexually transmitted infections. This development aims to expand patient-friendly access to STI testing by providing a convenient and private self-collection method.
OraSure stock jumps on FDA clearance for at-home STI kit
OraSure Technologies Inc. (NASDAQ:OSUR) shares jumped over 4% after receiving FDA clearance for its at-home urine collection kit for sexually transmitted infection (STI) testing. The kit, Colli-Pee Dx Urine Collection Kit, combines with Roche's molecular lab testing equipment to detect several STIs. This clearance aims to make STI testing more accessible, convenient, private, and personalized by enabling mail-in workflows for high-volume molecular STI testing.
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
OraSure Technologies, Inc. announced FDA clearance for its Colli-Pee™•Dx Urine Collection Kit. This kit, combined with Roche’s molecular diagnostic systems, allows for convenient at-home self-collection of urine samples for STI testing, including Chlamydia trachomatis and Neisseria gonorrhoeae. The clearance aims to expand access to patient-friendly testing, improve convenience, and support population-level screening programs.
OraSure (OSUR) director John P. Kenny granted 46,106 restricted shares
OraSure Technologies director John P. Kenny was granted 46,106 restricted shares of Common Stock at a price of $0.00 per share, increasing his direct holdings to 209,714 shares. These shares will vest in full on the earlier of June 3, 2027, or immediately before the company’s 2027 Annual Meeting of Stockholders, with vesting ceasing if he voluntarily leaves the Board. This grant is part of the company's Stock Award Plan and serves as equity compensation.
Director at OraSure (NASDAQ: OSUR) receives 46,106 restricted shares
OraSure Technologies director Steven Kyle Boyd was granted 46,106 restricted shares of common stock as part of the company's Stock Award Plan, at no cash cost. These shares will vest fully on the earlier of June 3, 2027, or immediately before the company’s 2027 Annual Meeting of Stockholders, provided he remains on the Board. Following this grant, Boyd directly holds 159,568 OraSure shares.
OraSure Technologies (OSUR) director receives 46,106-share restricted stock grant
OraSure Technologies director Robert W. McMahon was granted 46,106 restricted shares of common stock as board compensation. This grant, made at no cash cost, increases his direct holdings to 123,137 shares and will vest fully on June 3, 2027, or before the company's 2027 Annual Meeting of Stockholders. The shares were awarded under the OraSure Technologies, Inc. Stock Award Plan, with vesting contingent on his continued service on the Board of Directors.
OraSure Technologies (OSUR) director receives 46,106-share restricted stock grant
OraSure Technologies director John D. Bertrand was granted 46,106 shares of restricted common stock as an equity award, with no cash cost. These shares will vest in full on the earlier of June 3, 2027, or immediately before the company's 2027 Annual Meeting, provided he continues serving on the Board. Following this grant, Bertrand directly holds 79,767 OraSure shares.
OraSure (OSUR) director Nancy Gagliano receives 46,106-share stock award
OraSure Technologies (OSUR) director Nancy J. Gagliano was granted 46,106 restricted shares of common stock as a compensation award on June 3, 2026. These shares, valued at $0.00 each, will vest fully on the earlier of June 3, 2027, or prior to the company's 2027 annual stockholders meeting, provided she continues her board service. Following this grant, Gagliano directly holds a total of 185,055 shares.
OraSure Technologies (OSUR) director receives 46,106-share stock grant
OraSure Technologies director Lelio Marmora received a grant of 46,106 restricted shares of Common Stock as part of the company's Stock Award Plan. These shares were granted at no cash cost and will vest in full on the earlier of June 3, 2027, or before the 2027 Annual Meeting of Stockholders, provided Marmora continues his board service. After this transaction, Marmora directly holds 148,460 shares of OraSure Technologies.
OraSure Technologies Investors Approve Expanded Stock Plan, Governance Changes
OraSure Technologies stockholders approved an expanded stock award plan and governance changes at their annual meeting on June 3, 2026. This includes increasing shares for equity grants by 5 million, re-electing directors, ratifying auditors, and amending the board structure. Despite some opposition, these changes reflect strong investor backing for the company's approach to talent incentivization and corporate oversight.
Earnings call transcript: OraSure Technologies Q1 2026 misses earnings and revenue forecasts
OraSure Technologies reported a Q1 2026 earnings per share of -$0.24 and revenue of $27.9 million, missing analysts' forecasts. Despite operational challenges, the company's stock price remained stable, and it aims for future growth through upcoming product launches, including a rapid molecular self-test for chlamydia and gonorrhea. The company is focused on operational efficiencies and strategic initiatives, expecting FDA clearance for new products by mid-2026.
OraSure Technologies (NASDAQ: OSUR) OKs more equity awards and board declassification
OraSure Technologies' stockholders approved two key proposals at their 2026 annual meeting: an amendment to the 2000 Stock Award Plan authorizing 5,000,000 additional shares for equity awards, and an amendment to declassify the board of directors over a three-year period, transitioning to one-year terms for directors. Additionally, shareholders elected three Class II directors, ratified Grant Thornton LLP as the independent auditor for 2026, and approved the advisory vote on executive compensation. These actions aim to support employee retention through equity incentives and enhance corporate governance.
OraSure Technologies, Inc. - Common Stock (NQ: OSUR)
This article provides a list of recent news and financial updates concerning OraSure Technologies, Inc. (OSUR) stock. It includes announcements of earnings calls, quarterly financial results, strategic distribution agreements, and appearances at investor conferences, along with mentions in various financial news outlets regarding stock performance and analyst ratings.
OraSure Technologies Hits New 52-Week High at $4.00
OraSure Technologies, a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week high of $4.00, marking a significant increase from its previous low of $2.08. Despite this stock performance, the company faces financial challenges, including a negative return on equity and a lack of dividend yield. This movement highlights the stock's volatility within the microcap market, with observers watching how these trends develop given the company's financial standing.
Insiders Buying OraSure Technologies Might Wish They Invested More, Stock Gains 28%
The article suggests that while insiders at OraSure Technologies (NASDAQ: OSUR) have recently bought shares, their investments might be considered modest given the company's 28% stock price increase over the last year. It highlights that no single insider made a "largeness" purchase, and a significant portion of insider buying was through stock options awards during compensation. Despite some insider confidence, the article implies greater conviction might be warranted by larger, more frequent open market purchases.
OraSure Technologies Independent Director Acquires 195% More Stock
OraSure Technologies (NASDAQ:OSUR) Independent Director, Steven Boyd, recently purchased US$225k worth of the company's stock at US$3.00 per share, increasing his holding by 195%. This significant insider purchase suggests optimism despite the company not making a profit in the last year. The article highlights that insiders owning 6.1% of the company indicates a reasonable degree of alignment with shareholders and a potential belief that the share price is undervalued.
OraSure Technologies (OSUR) price target increased by 25.00% to 5.10
The article reports that the price target for OraSure Technologies (OSUR) has been increased by 25% to $5.10. This indicates a revised outlook for the company's stock by analysts.
OraSure director Steven Boyd purchases $224,750 in stock
OraSure Technologies Inc. director Steven Boyd recently acquired 75,000 shares of the company's common stock over three days, totaling $224,750. These purchases, made at prices between $2.98 and $3.02 per share, increased his direct ownership to 113,462 shares. The transactions occurred after OraSure's stock gained 28% in six months, despite a recent Q1 2026 earnings and revenue miss.
OraSure (OSUR) director has 21,305 shares withheld to cover tax on vested stock
OraSure Technologies director Nancy J. Gagliano reported a tax-related share disposition. On May 13, 2026, 21,305 shares of common stock were withheld at $3.02 per share to cover tax liabilities associated with the vesting of restricted shares. After this transaction, Ms. Gagliano directly holds 138,949 OraSure common shares.
Insider Buying: Steven Boyd Acquires 75,000 Shares of OraSure Te
Steven Boyd, a Director at OraSure Technologies Inc (OSUR), recently purchased 75,000 shares, increasing his total holdings to 113,462 shares. This transaction is part of a trend of six insider buys and no insider sells over the past year, indicating positive insider sentiment. Despite the insider confidence, the stock is currently trading at $3 per share, significantly above its GF Value estimate of $1.95, suggesting it is overvalued.
OraSure director Steven Boyd purchases $224,750 in stock
OraSure Technologies Inc. director Steven Boyd recently purchased 75,000 shares of the company's common stock for a total of $224,750. These purchases occurred between May 12 and May 14, 2026, with prices ranging from $2.98 to $3.02 per share, bringing his total direct ownership to 113,462 shares. This activity follows OraSure's Q1 2026 results, which missed EPS and revenue expectations.
[Form 3] ORASURE TECHNOLOGIES INC Initial Statement of Beneficial Ownership
OraSure Technologies director John D. Bertrand has filed a Form 3, which is an initial statement of beneficial ownership. This filing is administrative and indicates no share purchases, sales, or option exercises by Bertrand. Investors use Form 3 to track initial equity holdings of new company insiders.
Director at OraSure (NASDAQ: OSUR) awarded 33,661 restricted shares
OraSure Technologies director John D. Bertrand received a grant of 33,661 restricted shares of common stock as an equity award without cash cost. These shares will cliff vest on May 12, 2028, provided he continues to serve on the Board, otherwise, vesting will cease. This transaction was reported in a Form 4 filing and increases his direct holdings to 33,661 common shares.
